• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    TaiMed Biologics

    Societal CDMO

    U.S. Pharmacopeia (USP)

    Syngene International Ltd.

    Federal Equipment Company
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    TaiMed Biologics

    Societal CDMO

    U.S. Pharmacopeia (USP)

    Syngene International Ltd.

    Federal Equipment Company
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    01 F. Hoffman-La Roche

    ...

    Gil Roth07.14.11

    #1: F. Hoffman-La Roche

     

    Headcount                   80,653

    Year Established        1896

    Pharma Revenues     $35,629        -1%/-5%*

    Total Revenues          $45,643         1%/-3%*

    Net Income                  $8,548            9%/4%*

    R&D Budget                $7,845          -5%/-8%*
     

    * Converted at avg. exch. rate / based on reported currency (EUR)

     

    Top-Selling Drugs in 2010

    Drug

    Indication

    $

    (+/- %)

    Avastin

    oncology

    $6,212

    8%

    MabThera/Rituxan

    rheumatoid arthritis

    $6,111

    9%

    Herceptin

    breast cancer

    $5,220

    7%

    Pegasys/Copegus

    hepatitis C

    $1,582

    3%

    Lucentis

    wet age-related macular degeneration

    $1,402 60%

    Xeloda

    oncology

    $1,371

    18%

    Tarceva

    lung cancer

    $1,274

    6%

    CellCept

    transplantation

    $1,240

    -15%

    NeoRecormon/Epogin*

    anemia $1,235 -14%

    Boniva

    osteoporosis

    974

    0%

    Tamiflu

    influenza

    $839

    -72%

     

    Account for 77% of total biopharma sales, same as in 2009.


    PROFILE

    A funny thing happened on the way to the top. Just 18 months ago, Roche’s Avastin was on the march to becoming the world’s top-selling drug. A few failed trials and regulator/payor restrictions later, and Avastin wound up posting a 5% decline in 4Q10 and a 6% drop in 1Q11. Now it’s not even the top-selling drug at Roche! (That honor went to Rituxan in 1Q11.)


    It began with a missed endpoint in a Phase III trial in prostate cancer in March 2010 (noted in last year’s report, a long with failures in stomach and early colorectal cancers). Then the big shoe dropped in July 2010 when an FDA advisory panel questioned Avastin’s effectiveness as a breast cancer treatment. The panel voted 12-1 against keeping that indication for the drug, and the FDA followed its suggestion in December 2010.


    Avastin had received accelerated approval for Avastin in breast cancer in 2008, but the FDA cited several trials that showed Avastin failed to prolong overall survival in breast cancer patients or slow down the disease enough relative to the risks of Avastin’s side effects. It’s not the first time that a drug with accelerated approval ended up losing that indication, but it’s certainly the most high profile one.


    Roche, naturally, appealed the FDA’s ruling. So while the rest of the biotech industry was gathered in Washington DC in late June for the BIO conference, Roche executives were at the FDA’s White Oak Campus in Silver Spring to argue for Avastin’s reinstatement as a breast cancer treatment. The FDA’s ban is pending the outcome of the hearing process, but if it’s upheld, it could lead to a $1 billion drop in Avastin revenues. (The EMA still considers Avastin beneficial against breast cancer.) (UPDATE: The FDA upheld its ruling.)


    Meanwhile, the UK’s NICE considers Avastin too expensive for colorectal cancer treatment, given the benefits (six extra weeks of life, on average). Roche tried developing a new patient access scheme, but was rejected by the inaptly named institute. 


    Oh, and Roche is still battling to keep pharmacists from giving patients Avastin instead of Lucentis for wet macular degeneration, going so far as to highlight the higher death rate in patients treated with Avastin instead of Lucentis for that indication. 


    What does all this mean? Well, Roche has revised its peak sales estimates of Avastin from $8.7 billion to around $6.7 billion and, given that it posted $6.2 billion in 2010 sales, that may mean this is as good as it gets. That’s an awfully big number, but Roche was expecting a lot more from the Avastin engine when it acquired Genentech in 2008. (And Avastin did just post good results against ovarian cancer, so there’s still a potential for growth.)


    But enough about Avastin. What else is going on at our Top Biopharma company? In last year’s report, Tamiflu posted the biggest single-year revenue gain of any drug we covered, driven by H1N1 pandemic influenza stockpiling. This time around, it posted the biggest drop in revenues, losing $2.1 billion in revenues. (The next largest loss came from Merck’s Cozaar/Hyzaar hypertension drug, which shed $1.5 billion after losing patent protection.)


    This year didn’t start well for Roche, either. The pharma division posted a 10% drop in revenues (in CHF) in 1Q11, although a huge currency flux made those numbers look good in dollars. Even if you exclude the trailing sales of Tamiflu, Roche Pharma dropped 8% in the quarter.


    These declines, combined with some serious pipeline problems (as well as pricing pressures in Europe and healthcare reform dues in the U.S.), led Roche to break out the old Operation Axe-cellence (whoops! I meant “Excellence”). Following up on 2009’s restructuring and layoffs, Roche in September 2010 announced that it was reviewing operations. By November, it had decided that 4,800 jobs will be cut, 800 will be transferred and 700 will be outsourced, and more facilities will be shut down or consolidated. The company plans to cut, transfer or outsource the jobs of 2,650 people from sales and marketing, 1,350 from manufacturing, 800 from product development, 600 from research and early development, 640 from diagnostics and 260 from back-office functions. This latest round of cuts is designed to yield $2.4 billion in annual savings, but will cost $3.2 billion to implement, continuing through the end of 2012. There were R&D cuts, including the decision to cancel all RNA interference programs, but no talk of merging Roche and Genentech’s early R&D units.


    As I wrote, the restructuring wasn’t just the result of Avastin restrictions and no Tamiflu sales. Roche has had some late-stage pipeline problems, too. The Phase III trial of GLP-1 diabetes treatment taspoglutide was called off due to a high rate of gastrointestinal reactions. Roche cancelled the trial in September 2010 and returned rights to partner Ipsen in February 2011. At one point, taspoglutide had peak annual sales estimates of $2.0 billion.


    In August 2010, the FDA issued a Refuse To File letter for the accelerated BLA of Herceptin-followup T-DM1. The agency contended that the Phase II trials of T-DM1 that formed the basis of the BLA “did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population,” according to a Roche statement. The company is continuing its Phase III trial and expects to re-file in mid-2012.


    That said, Roche has around a dozen NMEs in Phase IIb or III, half of which have accompanying diagnostic tests for personalized medicine applications. At the recent ASCO meeting, Roche made a splash with vemurafenib, a melanoma treatment that reduced risk of dying by a mind-blowing 63% in one trial. In June 2011, Roche joined forces with Bristol-Myers Squibb to put vemurafenib in dual treatment with BMS’ recently approved Yervoy, to put a double-whammy on melanoma in certain genomically-defined patient populations. In all, the company hopes to make as many as 10 new drug submissions by the end of 2013.


    More than double the size of the #2 biopharma, Roche is in no danger of losing the top spot in our ranks. However, the company has a tough road ahead. Its products are effective but expensive, making them lightning-rods in the new age of payor-austerity. Also, the threat of biosimilars is still years ahead: Avastin is protected until 2018, by most standards, but Herceptin and Mabthera have patent expiries in Europe in 2014 and 2015, respectively. If Roche doesn’t get its next generation of bio-blockbusters on the market, it could be looking at a long, slow decline. (Or, of course, a mega-merger.)  —GYR
     


    THE LOWE DOWN

    The verdict on the merger? So far, so pretty good, at least from the outside. It’s created the biggest oncology company in the world, thanks to Avastin. And no matter how big the company is, Avastin is so big by itself that, for some time to come, it’ll be the biggest factor in how people see the whole company. Oncology being the ever-fragmented field it is, there always seem to be more patient populations and treatment combinations to add some Avastin to, which generates a steady supply of news for the analysts. Works in another indication? Things are good. Provisional approval being rolled back? Things aren’t so good.


    That’s sort of a shame, since they have a lot of other things going on, including a nearly J&J-like number of outside collaborations. But there are worse problems than having lots of attention paid to your huge-selling cancer drug, as many other companies can demonstrate.


    Of course, Roche (like everyone else) has had its pipeline problems and its rounds of layoffs. But overall, between these folks and Novartis, the Swiss pharma industry is looking pretty respectable these days. —Derek Lowe
     


    ACQUISITION NEWS

    Target: Marcadia Biotech

    Price: $287 million, plus $250 million in potential milestones

    Announced: December 2010

    What they said: Pretty much nothing. The company put out no press release about the purchase and only revealed the price two months later. In its annual report, the company noted, “In December Roche acquired Marcadia Biotech, a privately owned U.S. company focusing on the development of innovative therapeutics for metabolic diseases. Marcadia’s research and development programs on new peptide therapies for the treatment of type-2 diabetes and obesity will be integrated into Roche’s R&D portfolio. These include next generation peptides such as MAR701, currently in Phase I development for type-2 diabetes.”

     

    On the diagnostic side of the business (which, admittedly, is growing ever more intertwined with the drug side, much to my chagrin), Roche acquired BioImagene in August 2010 for $100 million in cash. BioImagene is a provider of digital pathology laboratory solutions, creating high-res, whole-slide digital images from glass microscope slides.


    In March 2011, Roche bought PVT, for approximately $90 million, plus $38 million in milestones. PVT’s product portfolio covers automation of pre- and post-analytical tasks, such as centrifuging, pipetting, sorting and archiving across a large variety of sample formats. The company’s products “enable clinical laboratories to reliably manage low to very high sample volumes and to arrange their lab space with great flexibility,” according to a Roche statement.
     


    OUTSOURCING NEWS

    With its November 2010 Operational Excellence restructuring announcement, Roche noted that it would transfer or outsource 1,500 jobs, in addition to 4,800 layoffs. It appears that the outsourcing activity involves sales reps, with several reports indicating that Tamiflu’s sales would be conducted by a contract sales organization.


    In September 2010, Argenta extended its small molecule discovery outsourcing collaboration with Roche unit Genentech. The agreement permitted Genentech to place projects with Argenta’s sister division, BioFocus. That division provides integrated medicinal chemistry, in vitro biology and ADME services. Argenta and Genentech began working together in 2005, with Argenta providing computer-aided drug design and other services to screen NCEs against Genentech-defined targets. Both Argenta and BioFocus are owned by Galapagos NV. 

    Next Profile: Amgen

    Related Searches
    • Outsourcing
    • Pharma
    • Phase II
    • Development
    Suggested For You
    U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail
    Adaptimmune, Genentech Enter Strategic R&D Collaboration Adaptimmune, Genentech Enter Strategic R&D Collaboration
    Roche, Shape Therapeutics Enter Strategic Gene Therapy Collaboration Roche, Shape Therapeutics Enter Strategic Gene Therapy Collaboration
    Ensuring Equitable Access to Next-generation Sequencing in Oncology Ensuring Equitable Access to Next-generation Sequencing in Oncology
    Japan First to Approve Roche’s Ronapreve to Treat COVID-19 Japan First to Approve Roche’s Ronapreve to Treat COVID-19
    Mimetas, Roche to Develop Human Disease Models for Drug Development Mimetas, Roche to Develop Human Disease Models for Drug Development
    Roche’s Actemra Receives FDA EUA to Treat COVID-19 Roche’s Actemra Receives FDA EUA to Treat COVID-19
    Centogene Appoints Dr. Michael Motz as CCO Centogene Appoints Dr. Michael Motz as CCO
    AGC Biologics Appoints Jun Takami GM of Chiba Site AGC Biologics Appoints Jun Takami GM of Chiba Site
    Spark Therapeutics Appoints CTO Spark Therapeutics Appoints CTO
    BioDuro-Sundia Appoints CEO BioDuro-Sundia Appoints CEO
    Financial Report: Roche Financial Report: Roche
    Affimed, Roche Explore AFM24, Tecentriq Combo Affimed, Roche Explore AFM24, Tecentriq Combo
    Samsung Biologics Names John Rim as President and CEO Samsung Biologics Names John Rim as President and CEO
    Mogene Mogene

    Related Breaking News

    • Breaking News | Industry News
      U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail

      U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail

      Will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022.
      09.15.21

    • Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Adaptimmune, Genentech Enter Strategic R&D Collaboration

      Adaptimmune, Genentech Enter Strategic R&D Collaboration

      To research, develop, and commercialize cancer-targeted Allogeneic T-cell therapies.
      09.07.21

    • Breaking News | Collaborations & Alliances | R&D
      Roche, Shape Therapeutics Enter Strategic Gene Therapy Collaboration

      Roche, Shape Therapeutics Enter Strategic Gene Therapy Collaboration

      ShapeTX will apply its RNA editing platform and leverage its AAVid technology platform for the development of gene therapy for various diseases.
      08.25.21


    • Bioanalytical Services
      Ensuring Equitable Access to Next-generation Sequencing in Oncology

      Ensuring Equitable Access to Next-generation Sequencing in Oncology

      Recent advances in sequencing techniques have transformed cancer treatment.
      Gang Song, Ph.D., CEO & Co-Founder, Pillar Biosciences 08.20.21

    • Trials & Filings
      Japan First to Approve Roche’s Ronapreve to Treat COVID-19

      Japan First to Approve Roche’s Ronapreve to Treat COVID-19

      Full approval is based on a global phase III trial which found casirivimab and imdevimab reduced hospitalization or death by 70%.
      07.21.21

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 30
    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Happi

    Latest Breaking News From Happi

    Is Dr. Barbara Sturm Skincare Considering a Sale?
    YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
    Christian Siriano Appointed Olay’s First Chief Drop Officer
    Ink World

    Latest Breaking News From Ink World

    MicroDynamics, All Printing Resources Partner to Represent Veritas
    Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
    Siegwerk’s Climate Targets Validated by SBTi
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 30
    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login